Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of extracorporeal membrane oxygenation in the management of rapidly progressive interstitial lung disease due to anti-melanoma differentiation-associated gene 5 antibody dermatomyositis: A case series and brief literature review.

JHLT open·2026
Same author

A rare case report of decompensated cirrhosis from hereditary hemochromatosis following lung transplant in a person with cystic fibrosis.

Respiratory medicine case reports·2026
Same author

Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials.

Transplantation·2025
Same author

Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials.

Transplantation direct·2025
Same author

One-year lung transplantation outcomes for engineered stone countertop workers with silicosis at a single center in Southern California, 2019 to 2023.

JHLT open·2025
Same author

Single-center perioperative management and 1-year heart transplantation outcomes for patients with adult congenital heart disease.

JHLT open·2025

Related Experiment Video

Updated: Jul 14, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Lung transplantation and pulmonary hypertension.

Gordon Yung1

  • 1Division of Pulmonary and Critical Care Medicine, University of California San Diego, UCSD Medical Center, San Diego, California 92103-8373, USA. gyung@ucsd.edu

Seminars in Cardiothoracic and Vascular Anesthesia
|May 31, 2007
PubMed
Summary

Pulmonary hypertension significantly impacts lung transplantation decisions and outcomes. Understanding disease progression and the transplant process is crucial for effective patient care and communication.

More Related Videos

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP
06:55

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP

Published on: February 14, 2022

Related Experiment Videos

Last Updated: Jul 14, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP
06:55

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP

Published on: February 14, 2022

Area of Science:

  • Pulmonology
  • Cardiology
  • Transplant Surgery

Background:

  • Pulmonary hypertension (PH) presents complex challenges in lung transplantation.
  • Effective management requires understanding PH natural history and treatment options.

Purpose of the Study:

  • To highlight the multifaceted impact of PH on lung transplantation.
  • To emphasize the need for comprehensive knowledge among physicians caring for PH patients.

Main Methods:

  • Review of current literature on PH and lung transplantation.
  • Analysis of factors influencing patient selection, risks, and outcomes.

Main Results:

  • PH influences all stages of lung transplantation, from selection to post-operative results.
  • Knowledge of PH progression, treatments, and transplant allocation is vital.

Conclusions:

  • Optimal patient selection and management in lung transplantation require a deep understanding of PH.
  • Effective communication between referring physicians and transplant centers is paramount for successful outcomes.